AIDX AIDX
Company Profile ↓Company Overview
AIDX (AIDX) is a publicly traded company listed on . The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Why Investors Should Care
Revenue has grown at a 19.8% CAGR over the past five years.
Recent Developments
- Dec 2025 Revenue of $2.05M (+16.7% YoY); net profit $-3.74M.
- Trailing 12 Months Year-on-year growth — revenue +16.7%.
- 5-Year Trend Long-term compounding — revenue CAGR 19.8%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 19.83% |
| 1 Year: | 16.71% |
Stock Price Performance
| 1 Year: | -98.15% |
| 6 Months: | - |
| 3 Months: | -70.38% |
| 1 Month: | -25.20% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- RSI (14)32.68 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 19.8% over 5 years.
CONS
- Trading 98.2% below its 52-week high.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2025 | Mar 2026 |
|---|---|---|
| Revenue | 553.82K | 353.38K |
| Gross Profit | 165.79K | 62.88K |
| Operating Income | -772.18K | -1.44M |
| Net Income | -764.58K | -2.17M |
| Diluted EPS | -0.16 | -0.28 |
| R&D Expense | 136.83K | 153.48K |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Revenue | 1.42M | 1.75M | 2.05M |
| Cost of Revenue | 1.32M | 1.39M | 1.44M |
| Gross Profit | 109.14K | 360.31K | 604.54K |
| Operating Expenses | 6.47M | 6.02M | 3.94M |
| Operating Income | -6.36M | -5.66M | -3.33M |
| EBITDA | -6.20M | -5.40M | -3.50M |
| Interest Expense | 27.91K | 12.65K | 156.21K |
| Pretax Income | -6.39M | -5.55M | -3.74M |
| Tax Provision | 0 | 0 | 0 |
| Net Income | -6.39M | -5.55M | -3.74M |
| Diluted EPS | -0.62 | -0.54 | -0.36 |
| R&D Expense | - | 1.26M | 592.57K |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Total Assets | - | 3.58M | 4.14M |
| Total Equity | 4.29M | 1.51M | -19.23K |
| Cash & Equivalents | - | 1.78M | 1.03M |
| Total Liabilities | - | 2.08M | 4.16M |
| Current Liabilities | - | 1.36M | 2.46M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2024 | Dec 2025 |
|---|---|---|
| Operating Cash Flow | -2.60M | -1.92M |
| Financing Cash Flow | 293.33K | 1.16M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Gross Margin % | 7.7% | 20.6% | 29.6% |
| Operating Margin % | -446.6% | -323.1% | -162.9% |
| Net Margin % | -448.7% | -316.8% | -182.8% |
| ROE % | -149.1% | -368.8% | 19,447.7% |
| ROCE % | - | -253.9% | -199.0% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for AIDX
symbol__ Stock Quote Price and Forecast - CNN
<a href="https://news.google.com/rss/articles/CBMiUEFVX3lxTE13bjFzelpydHRjOUtIZFhTeGJFdkw5WEZlWlNHakNzbXh5aFRvbE5TNmZXZHp4ZkJlOF94eGw2dllyRGZIbDNDd0s3eHN3NElx?oc=5" target="_blank">symbol__ Stock Quote Price and Forecast</a> <fon…
Healwell AI (TSX:AIDX) Stock Fair Value Falls As Analysts Trim Growth Assumptions - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMikAFBVV95cUxOZF9iOW41eUgya3o5V01DSm9WRl9VeHZmcEVvS0J2V2g2OFl0SnlmWmVldEtRNHlGUXA2V05jOTdZUE9xb2FxYnRieEtjbldPOHppSWRqczltWDVkSnE4MFBoMFNoZXlLejQ1dXhMd09Md3VlNnVwQUcyOTE3a3FQdUZMb05IRXg2NUJBX1…
After Taipei, Tokyo and Seoul, 20/20 BioLabs to discuss deal options - Stock Titan
<a href="https://news.google.com/rss/articles/CBMivwFBVV95cUxQal91eEVZSDRVcHpzUlBQVVFDb2xQTzJKamNsTVh1NnRsM3dmM1VsYkliM3lDOF9VdmJYbGJPdjc2dWxUS1ZoWUZlcmUzTHFuMVY4dkpEU0o1WXZMem1vUkNPVG93YVNXU2hFTUw1a0ZBb01lMEtyTzl6VXlkMHZLOExmaHJlTjZqY3drTU…
HealWELL AI Inc. Class A Revenue Breakdown – TSX:AIDX - TradingView
<a href="https://news.google.com/rss/articles/CBMic0FVX3lxTE55ZklTRmZzZ2FVV3hLYWt0VlhMaVdnVy01TUQ3S0MwSHh1RUs3bEp6MVRva2lpaUV2aTREbmxXNmZ4UDEyampjZ0V3MUFxZTl4RnIxSkxqR0o2WmdWUk5MbzdoMVllV1lMMVJEUUd5YWRDMDg?oc=5" target="_blank">HealWELL AI …
20/20 BioLabs Enters Temporary Standstill Agreement Limiting Series E Preferred Stock Conversions - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMizAFBVV95cUxPd2tLcTBVSV9MS3BvLVVEZ29QeFpjSXE0RXdCeWFyVTY2QWVseFdUdjVxc1BlQW9ObUZMay1TdTBpaWFJUUJkM05EdFNIX3paeXdtZFh5VTJrekVJUnRzUWNOOFdrS3ZDbjBPZDlzN21fd2ZMSkEtdHlCSm5FXzFNaXMyMWRIZFdBRDVoOW…
20/20 BioLabs Enters Temporary Standstill Agreement Limiting Series E Preferred Stock Conversions - Moomoo
<a href="https://news.google.com/rss/articles/CBMisAFBVV95cUxOeTVWVkhYbERCR3Nqa3hKSEoxQ2NWeS1IcXY1VXBxOUpQMi1UeEhfZzNlU0FBMlhEZ0tUTUM4MEJlNXpSVFhmTm1oUXU4c0drM0t5bGIxZjR1MUZqZ3JmbEE5UllKckc1Sm1nZ1NxRFYzVFVGUGhzeHJsMDIxRU9CNGlfQ003N1ZVSzZ4Zl…
AIDX — Frequently Asked Questions
What is the current share price of AIDX?
As of 2026-08-05 17:25 PDT, AIDX trades at $0.44 on NASDAQ/NYSE. Its 52-week range is $0.40 to $23.85.
What is the P/E ratio of AIDX?
AIDX trades at a trailing price-to-earnings (P/E) ratio of -1.22.
Is AIDX a good stock to buy?
This page provides a data-driven analysis of AIDX, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.